Remy Durand - May 20, 2024 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC. (ALPN)

Role: Chief Business Officer
Signature: /s/ James Paul Rickey, attorney-in-fact
Stock symbol: ALPN
Transactions as of: May 20, 2024
Transactions value $: $0
Form type: 4
Date filed: 5/20/2024, 08:02 PM
Previous filing: May 10, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALPN	Common Stock	Disposed to Issuer		-102K	-76.61%		31.2K	May 20, 2024	Direct	F1, F2, F3
transaction	ALPN	Common Stock	Disposed to Issuer		-31.2K	-100%		0	May 20, 2024	Direct	F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALPN	Stock Option (Right to buy)	Disposed to Issuer		-2.64K	-100%		0	May 20, 2024	Common Stock	2.64K	$4.09	Direct	F5, F6, F7, F8
transaction	ALPN	Stock Option (Right to buy)	Disposed to Issuer		-26.9K	-100%		0	May 20, 2024	Common Stock	26.9K	$3.23	Direct	F5, F6, F7, F8
transaction	ALPN	Stock Option (Right to buy)	Disposed to Issuer		-70.2K	-100%		0	May 20, 2024	Common Stock	70.2K	$13.20	Direct	F5, F7, F8, F9
transaction	ALPN	Stock Option (Right to buy)	Disposed to Issuer		-113K	-100%		0	May 20, 2024	Common Stock	113K	$13.30	Direct	F5, F7, F8, F10
transaction	ALPN	Stock Option (Right to buy)	Disposed to Issuer		-109K	-100%		0	May 20, 2024	Common Stock	109K	$7.55	Direct	F5, F7, F8, F11
transaction	ALPN	Stock Option (Right to buy)	Disposed to Issuer		-78K	-100%		0	May 20, 2024	Common Stock	78K	$18.33	Direct	F5, F7, F8, F12

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remy Durand is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F2	(Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.
F3	Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date.
F4	Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration.
F5	The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F6	The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
F7	Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.
F8	(Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payments or other consideration being made in respect thereof.
F9	One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F10	One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F11	One-fourth (1/4) of the shares subject to the option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F12	One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.